Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.
about
The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.Correlation of immune phenotype with IDH mutation in diffuse glioma.Aligning Digital CD8(+) Scoring and Targeted Next-Generation Sequencing with PD-L1 Expression: A Pragmatic Approach in Early-Stage Squamous Cell Lung Carcinoma.PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis.A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.Reprogramming of stromal fibroblasts by SNAI2 contributes to tumor desmoplasia and ovarian cancer progression.PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level.Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis.Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis.Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung CancerPrognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms
P2860
Q33618747-5059F39F-D9B6-45CE-8578-30FF4395DF26Q38771020-343768A1-D49A-4B22-92E6-7A60A5E70EEFQ40496586-B2E78517-870E-4595-9F06-2C5F477A227FQ40974150-2DA0143A-DD48-432A-BE92-578BCAEDFA74Q41306256-EE6F2769-B9A7-421B-A200-58D186B6A723Q41579669-6319E8B2-B173-4248-8D3D-EF0FDB62144AQ42682574-4DDCA848-A9C7-4CEF-B784-C81F712641E0Q47135594-8B74A565-D827-4744-85DA-B4373BF995C6Q47140225-52C8BBD3-6861-489D-9F58-9CD384975221Q47214499-831780FC-9E75-4D02-B22E-BA932CEDE6E2Q48190359-1A910485-B378-4175-8640-D43C1291DCDAQ49494082-FD5A83A7-A03E-4021-A63F-BC4292B494B1Q52684139-C6324A43-29F4-4907-9BC5-0865A4AA4652Q55440274-A763CFA8-308D-4588-B7BC-BE73D1300034Q57174372-F224EBA7-CF18-493F-8CD8-F68D3337EB19Q57493798-BD8B0FF7-99E9-450E-B181-AED024A38A5B
P2860
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Programmed Cell Death Ligand 1 ...... with Immune Microenvironment.
@en
type
label
Programmed Cell Death Ligand 1 ...... with Immune Microenvironment.
@en
prefLabel
Programmed Cell Death Ligand 1 ...... with Immune Microenvironment.
@en
P2093
P1476
Programmed Cell Death Ligand 1 ...... with Immune Microenvironment.
@en
P2093
Aaron N Hata
Emine Bozkurtlar
Eugene J Mark
Hironori Uruga
Jeffrey A Engelman
Justin F Gainor
Maria Gomez-Caraballo
Meghan J Campo
Michael Lanuti
P304
P356
10.1016/J.JTHO.2016.08.134
P577
2016-08-24T00:00:00Z